XML 16 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities:    
Net income (loss) $ (19,498) $ 33,820
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:    
Non-cash royalty revenue related to sale of future royalties (6,535) (3,962)
Non-cash interest expense on liability related to sale of future royalties 5,045 5,050
Stock-based compensation 6,363 5,177
Depreciation and amortization 3,715 2,973
Other non-cash transactions (617) (938)
Changes in operating assets and liabilities:    
Accounts receivable, net (19,730) 722
Inventory 96 441
Other assets 4,294 2,809
Accounts payable (34) 2,241
Accrued compensation 4,046 3,607
Accrued clinical trial expenses 2,376 1,039
Other accrued expenses 2,176 1,811
Interest payable (54) (3,750)
Deferred revenue (7,027) 1,993
Other liabilities 1,736 10,279
Net cash (used in) provided by operating activities (23,648) 63,312
Cash flows from investing activities:    
Purchases of investments (31,452) (24,432)
Maturities of investments 69,377 73,434
Sales of investments 0 5,215
Purchases of property, plant and equipment (1,679) (1,059)
Net cash provided by investing activities 36,246 53,158
Cash flows from financing activities:    
Payment of capital lease obligations (1,723) (1,098)
Proceeds from shares issued under equity compensation plans 6,096 1,685
Net cash provided by financing activities 4,373 587
Effect of exchange rates on cash and cash equivalents 8 30
Net increase in cash and cash equivalents 16,979 117,087
Cash and cash equivalents at beginning of period 55,570 12,365
Cash and cash equivalents at end of period 72,549 129,452
Supplemental disclosure of cash flow information:    
Cash paid for interest $ 5,244 $ 7,855